AllianceBernstein
ADCT icon

AllianceBernstein’s ADC Therapeutics ADCT Stock Holding History

AllianceBernstein’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Buy
108,470
+66,620
+159% +$194K ﹤0.01% 2837
2026
Q1 		$148K Hold
41,850
– – ﹤0.01% 3112
2025
Q4 		$148K Sell
41,850
-7,740
-16% -$31.4K ﹤0.01% 3121
2025
Q3 		$198K Hold
49,590
– – ﹤0.01% 3074
2025
Q2 		$133K Buy
49,590
+27,570
+125% +$58K ﹤0.01% 3131
2025
Q1 		$31K Hold
22,020
– – ﹤0.01% 3166
2024
Q4 		$43.8K Hold
22,020
– – ﹤0.01% 3194
2024
Q3 		$69.4K Hold
22,020
– – ﹤0.01% 3165
2024
Q2 		$69.6K Buy
+22,020
New +$87.5K ﹤0.01% 3161
2023
Q1 		– Sell
-2,824,956
Closed -$10.8M – 3175
2022
Q4 		$10.8M Sell
2,824,956
-90,204
-3% -$361K ﹤0.01% 1061
2022
Q3 		$14.1M Sell
2,915,160
-46,464
-2% -$337K 0.01% 942
2022
Q2 		$23.5M Buy
2,961,624
+4,568
+0.2% +$43.2K 0.01% 809
2022
Q1 		$43.4M Buy
2,957,056
+149,333
+5% +$2.37M 0.02% 644
2021
Q4 		$56.7M Buy
2,807,723
+153,506
+6% +$3.7M 0.02% 586
2021
Q3 		$72.1M Sell
2,654,217
-399,031
-13% -$10.2M 0.03% 519
2021
Q2 		$74.3M Buy
3,053,248
+422,757
+16% +$9.81M 0.03% 519
2021
Q1 		$64.2M Buy
2,630,491
+829,755
+46% +$24M 0.03% 533
2020
Q4 		$57.6M Buy
1,800,736
+502,171
+39% +$16.5M 0.03% 540
2020
Q3 		$42.8M Buy
1,298,565
+370,988
+40% +$16.1M 0.02% 578
2020
Q2 		$43.4M Buy
+927,577
New +$35.2M 0.03% 551

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AllianceBernstein's ADCT Position: Q2 2026 in Review

AllianceBernstein increased its ADC Therapeutics (ADCT) stake by 159% in Q2 2026, buying an estimated $194K and bringing the position to 108,470 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2837.

AllianceBernstein first reported a position in ADCT in Q2 2020 and has held it in 20 quarters since. The position peaked at $74.3M in Q2 2021. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • AllianceBernstein held 108,470 shares of ADC Therapeutics worth $407K as of Q2 2026.
  • AllianceBernstein bought 66,620 ADC Therapeutics shares in Q2 2026, an estimated $194K.
  • ADC Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2837 holding.
  • AllianceBernstein first reported a position in ADC Therapeutics in Q2 2020 and has held it in 20 quarters since.
  • AllianceBernstein's ADC Therapeutics position peaked at $74.3M in Q2 2021.
  • 114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.